These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. Faiella A; Riccardi F; Cartenì G; Chiurazzi M; Onofrio L J Oncol; 2022; 2022():5179182. PubMed ID: 35069735 [TBL] [Abstract][Full Text] [Related]
66. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma. Schmidinger M; Danesi R Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618 [TBL] [Abstract][Full Text] [Related]
67. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Yu SS; Quinn DI; Dorff TB Onco Targets Ther; 2016; 9():5825-5837. PubMed ID: 27713636 [TBL] [Abstract][Full Text] [Related]
68. C-MET as a new therapeutic target for the development of novel anticancer drugs. Cañadas I; Rojo F; Arumí-Uría M; Rovira A; Albanell J; Arriola E Clin Transl Oncol; 2010 Apr; 12(4):253-60. PubMed ID: 20462834 [TBL] [Abstract][Full Text] [Related]
69. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Limaye PB; Bowen WC; Orr AV; Luo J; Tseng GC; Michalopoulos GK Hepatology; 2008 May; 47(5):1702-13. PubMed ID: 18398918 [TBL] [Abstract][Full Text] [Related]
70. Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Leonis MA; Thobe MN; Waltz SE Future Oncol; 2007 Aug; 3(4):441-8. PubMed ID: 17661719 [TBL] [Abstract][Full Text] [Related]
71. Redundant roles for Met docking site tyrosines and the Gab1 pleckstrin homology domain in InlB-mediated entry of Listeria monocytogenes. Basar T; Shen Y; Ireton K Infect Immun; 2005 Apr; 73(4):2061-74. PubMed ID: 15784547 [TBL] [Abstract][Full Text] [Related]
72. Immunoblot analysis of c-Met expression in human colorectal cancer: overexpression is associated with advanced stage cancer. Zeng Z; Weiser MR; D'Alessio M; Grace A; Shia J; Paty PB Clin Exp Metastasis; 2004; 21(5):409-17. PubMed ID: 15672865 [TBL] [Abstract][Full Text] [Related]
73. Invasive growth: from development to metastasis. Comoglio PM; Trusolino L J Clin Invest; 2002 Apr; 109(7):857-62. PubMed ID: 11927611 [No Abstract] [Full Text] [Related]
74. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Xin X; Yang S; Ingle G; Zlot C; Rangell L; Kowalski J; Schwall R; Ferrara N; Gerritsen ME Am J Pathol; 2001 Mar; 158(3):1111-20. PubMed ID: 11238059 [TBL] [Abstract][Full Text] [Related]
75. Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stroma in vitro. Lang SH; Clarke NW; George NJ; Testa NG Clin Exp Metastasis; 1999 Jun; 17(4):333-40. PubMed ID: 10545020 [TBL] [Abstract][Full Text] [Related]
76. Interactions between scatter factors and their receptors: hints for therapeutic applications. Trusolino L; Pugliese L; Comoglio PM FASEB J; 1998 Oct; 12(13):1267-80. PubMed ID: 9761771 [TBL] [Abstract][Full Text] [Related]
77. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Donate LE; Gherardi E; Srinivasan N; Sowdhamini R; Aparicio S; Blundell TL Protein Sci; 1994 Dec; 3(12):2378-94. PubMed ID: 7756992 [TBL] [Abstract][Full Text] [Related]
78. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. Comoglio PM EXS; 1993; 65():131-65. PubMed ID: 8380735 [TBL] [Abstract][Full Text] [Related]
79. Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Weidner KM; Hartmann G; Sachs M; Birchmeier W Am J Respir Cell Mol Biol; 1993 Mar; 8(3):229-37. PubMed ID: 8383506 [TBL] [Abstract][Full Text] [Related]